Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 /PRNewswire/ — Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special intent acquisition business affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based mostly in South San Francisco, Calif., these days introduced that they have mutually agreed to terminate the beforehand declared Settlement and Program of Merger (the “Merger Agreement”), successful immediately.

As expected by Cayman Islands legislation, BAC will convene the beforehand postponed amazing typical assembly of shareholders on Tuesday, June 14, 2022, at 9:00 AM Japanese Time.  As previously declared, the remarkable common meeting will come about at the offices of Ellenoff Grossman and Schole LLP located at 1345 Avenue of the Americas, 11th Ground, New York, New York, 10105 and just about through dwell webcast at https://www.cstproxy.com/biotechacquisition/2022.

As a outcome of the termination of the Merger Arrangement, at the amazing common meeting, BAC intends that none of the proposed resolutions to approve the Merger Agreement and the similar resolutions will be set ahead for thought and approval by BAC’s shareholders and that the incredible normal meeting will be adjourned indefinitely.  In light-weight of the termination of the Merger Arrangement, the proposed business enterprise mix will not be concluded and any standard shares submitted for redemption will not be redeemed at this time and will be returned to the respective holder, broker or financial institution in the manner explained in the definitive proxy statement for the extraordinary general assembly.  BAC intends to proceed to go after the consummation of a small business combination with an correct target. Extra information and facts about the termination of the Business enterprise Combination will be supplied in a Existing Report on Form 8-K to be submitted by BAC with the SEC and obtainable at www.sec.gov.

Michael Shleifer, Ph.D., chairman and CEO of BAC, co-founder and handling lover of SPRIM World Investments explained, “We would like Blade ongoing achievement as they continue on to acquire slicing-edge science and a scientific-stage pipeline targeting health conditions that remain undertreated. BAC continues to be dedicated to finding a lifestyle-sciences associate that can produce price for our shareholders.”

Wendye Robbins, M.D., president and CEO of Blade stated, “Blade remains concentrated on our progress strategies, especially for our company’s differentiated direct asset, cudetaxestat, a non-competitive autotaxin inhibitor which is anticipated to enter a prepared period 2 clinical review in people with idiopathic pulmonary fibrosis.”

About Biotech Acquisition Company

Biotech Acquisition Company raised $230 million in its preliminary public providing in January 2021. BAC’s Course A standard shares and warrants trade on the Nasdaq Capital Market place below the symbols “BIOT” and “BIOTW,” respectively. BAC is a blank verify organization, included as a Cayman Islands exempted business, fashioned for the reason of effecting a merger, amalgamation, share exchange, asset acquisition, share buy, reorganization or other similar organization mix with a person or much more businesses. BAC thinks that a enterprise blend with a company focused on the healthcare sector will enhance the history and skills of SPRIM World-wide Investments, a world-wide financial commitment agency in the lifestyle sciences and health care industries, which is an affiliate of BAC and of a number of associates of BAC’s management crew. BAC is led by Dr. Michael Shleifer, its CEO and chairman.

About Blade Therapeutics

Blade Therapeutics, Inc. is a biopharmaceutical company focused on building slicing-edge therapies for debilitating, incurable fibrotic and neurodegenerative conditions that influence millions of persons around the globe. The firm has deep experience in novel biological pathways – such as autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-hurt responses connected with fibrotic and neurodegenerative diseases. Blade expects to progress a differentiated pipeline of oral, tiny-molecule therapies that consist of a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for the possible remedy of lung, liver and cardiac fibrosis or neurodegenerative disorders. The firm’s concentrated strategy offers the potential to produce disease-modifying, lifestyle-preserving therapies. Check out www.blademed.com for extra information and observe Blade on LinkedIn.

Particular Notice Pertaining to Ahead-On the lookout Statements

Particular statements included in this press release that are not historic facts but fairly are forward-looking statements. Forward-hunting statements normally are accompanied by terms this sort of as “consider,” “may well,” “will,” “estimate,” “carry on,” “anticipate,” “intend,” “count on,” “need to,” “would,” “strategy,” “long term,” “outlook,” and similar expressions that predict or show long term occasions or trends or that are not statements of historic matters, but the absence of these text does not necessarily mean that a statement is not forward-hunting. These ahead-searching statements contain, but are not constrained to, statements relating to estimates and forecasts of other general performance metrics and projections of marketplace prospect. These statements are primarily based on many assumptions, regardless of whether or not identified in this push launch, and on the present anticipations of BAC’s and Blade’s respective administration and are not predictions of true efficiency. These forward-looking statements are supplied for illustrative reasons only and are not intended to provide as, and have to not be relied on by any investor as, a assurance, an assurance, a prediction or a definitive statement of simple fact or likelihood. Genuine occasions and instances are complicated or extremely hard to forecast and will vary from assumptions. A lot of real situations and conditions are past the handle of BAC and Blade. Some vital elements that could lead to genuine results to vary materially from those people in any ahead-hunting statements could consist of modifications in domestic and foreign enterprise, market, financial, political and legal situations. These ahead-hunting statements are issue to a number of pitfalls and uncertainties, such as, BAC’s or Blade’s capacity to execute its respective organization ideas and strategy the capacity to guard and enrich Blade’s respective corporate name and brand the effects from potential regulatory, judicial, and legislative modifications in Blade’s business the timing, fees, perform, and result of scientific trials and potential preclinical studies and clinical trials, together with the timing of the initiation and availability of facts from such trials the timing and probability of regulatory filings and approvals for merchandise candidates whether regulatory authorities figure out that additional trials or facts are important in purchase to receive approval the prospective industry dimension and the dimensions of the patient populations for products candidates, if approved for commercial use, and the sector possibilities for merchandise candidates the capability to find and acquire complementary items or merchandise candidates and integrate these into Blade’s small business and, the uncertain consequences of the COVID-19 pandemic and all those variables established forth in paperwork of BAC filed, or to be submitted, with SEC. The foregoing listing of hazards is not exhaustive.

If any of these dangers materialize or our assumptions verify incorrect, true effects could vary materially from the outcomes implied by these ahead-searching statements. There may perhaps be added hazards that neither BAC nor Blade presently know or that BAC and Blade presently think are immaterial that could also trigger precise success to vary from those contained in the forward-seeking statements. In addition, forward-hunting statements mirror BAC’s and Blade’s current anticipations, programs and forecasts of potential situations and sights as of the day of this press launch. BAC and Blade foresee that subsequent events and developments will cause BAC’s and Blade’s assessments to modify. Nonetheless, even though BAC and Blade may well elect to update these forward-on the lookout statements at some level in the long term, BAC and Blade specifically disclaim any obligation to do so. These forward-searching statements really should not be relied on as representing BAC’s or Blade’s assessments as of any day subsequent to the date of this push launch. Appropriately, undue reliance ought to not be positioned on the ahead-seeking statements.

View primary content material to obtain multimedia:https://www.prnewswire.com/information-releases/biotech-acquisition-enterprise-and-blade-therapeutics-mutually-concur-to-terminate-company-mix-arrangement-301566521.html

Source Biotech Acquisition Firm